Credits2

  2. Home
  3. Credits2

 

Search

Page 5 of 5
Results 301 - 346 of 346
biosims-gastro1
Biosimilars: The New Era of Gastroenterology Management Considerations
psoriasis-nurse
Psoriasis Management Considerations: What Would You Do?
psoriasis-case3
Jamie Develops Complications with Her Psoriasis
psoriasis-case2
Psoriasis: Three Case Studies in the Primary Care Setting
psoriasis-case1
Cindy Has a Complex Case of Psoriasis
9707-ella
Famous People with Diabetes: Ella Fitzgerald
9707-jerry
Famous People with Diabetes: Jerry Garcia
aims icon-target
Targeting B-cells in Primary Progressive MS (PPMS)
aims icon-comorb
Comorbidities and Selection of DMTs
aims icon-gut
The Gut Microbiota in MS
aims icon-early
Early MS: Induction Therapy and Escalation Strategies
aims icon-vitamin
Vitamin D: Modifiable Risk Factor and its Role in the Management of Patients with MS
t2diabetes-slides1
Download Slides: Optimizing Diabetes Treatment in a Sea of Treatment Options
No image set
UIP, IPF, NSIP, CHP: Making Sense of the Letters
t2diabetes-slides2
Download Slides: Advancing T2DM Therapy with Confidence
t2diabetes-louise
Getting to Goal Can Be Difficult: Louise
t2diabetes-brian
Getting to Goal Can Be Difficult: Brian
IL-rheum-case3
Considering Biosimilars in Patients Failing their Initial Biologic
IL-rheum-case2
When to Switch? Biologically Experienced Patients with Spondyloarthritis
IL-rheum-case1
Innovator or Biosimilar for a Patient with Rheumatoid Arthritis
IL-gastro-case3
Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?
IL-gastro-case2
Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
IL-gastro-case1
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
IL-derm-case3
Switching Between Biologics: Is a Biosimilar an Option?
IL-derm-case2
When to Switch? Biologically Experienced Psoriasis Patients
IL-derm-case1
Innovator or Biosimilar for a Patient with Psoriasis
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
IL-fund-case1
What is a Biologic?
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
biosims-full7
Biosimilars: As Safe and Effective as the Reference Product?
biosims-green
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
No image set
Radiologic Features of IPF
lgmw-05
A 30 y/o Female w/2-year History of Shoulder Weakness and Elevated AST and ALT
lgmw-04
32 y/o Male w/Progressive Weakness, Dilated Cardiomyopathy & Respiratory...
lgmw-03
A 60 y/o Male w/4-year History Of Shoulder Weakness
biosims-full8
Biosimilars in Clinical Practice: Interchangeability and Extrapolation
No image set
Individualizing Patient Education in Treatment Choice: Practical Strategies
No image set
Addressing Common Barriers to Adherence
9529-00028
Approach to Genetic Testing in Myopathies
9529-00014
Molecular Diagnosis of Limb-Girdle Muscle Weakness
Page 5 of 5

Search